Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. by Keith R Edwards, Jaya Goyal, Tatiana Plavina, Julie Czerkowicz, Susan Goelz, Ann Ranger, Diego Cadavid, Jeffrey L Browning

Get full text

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis by Giancarlo Comi, Mark S. Freedman, José E. Meca-Lallana, Patrick Vermersch, Byoung Joon Kim, Alexander Parajeles, Keith R. Edwards, Ralf Gold, Houari Korideck, Jeffrey Chavin, Elizabeth M. Poole, Patricia K. Coyle

Get full text

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study) by Annette F. Okai, Lilyana Amezcua, Regina R. Berkovich, Angel R. Chinea, Keith R. Edwards, Brian Steingo, Aljoeson Walker, Alan K. Jacobs, Nadia Daizadeh, Mitzi J. Williams, the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators

Get full text

Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases by Seth N. Levin, Shruthi Venkatesh, Katie E. Nelson, Yi Li, Ines Aguerre, Wen Zhu, Karman Masown, Kathryn T. Rimmer, Claudiu I. Diaconu, Kaho B. Onomichi, Victoria M. Leavitt, Libby L. Levine, Rebecca Strauss‐Farber, Wendy S. Vargas, Brenda Banwell, Amit Bar‐Or, Joseph R. Berger, Andrew D. Goodman, Erin E. Longbrake, Jiwon Oh, Bianca Weinstock‐Guttman, Kiran T. Thakur, Keith R. Edwards, Claire S. Riley, Zongqi Xia, Philip L. De Jager, Multiple Sclerosis Resilience to COVID‐19 (MSReCOV) Collaborative

Get full text